Clinical Trial Detail

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine

Research Study Number	9213
Principal Investigator	K.Scott Baker
Phase	II

Look up trial at NIH

Research Study Description

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number	9213
Contact	Seattle Cancer Care Alliance Intake Office
Telephone	800-804-8824 / 206-606-1024

Keywords: Leukemia, Acute Myeloid (AML); Anemia, Aplastic; Fanconi Anemia; Hematologic Malignancies; Leukemia; Pediatric Cancers, Miscellaneous; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Neoplasms; Anemia; Preleukemia; Bone Marrow Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019